• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Thrombopoietin-receptor agonists in perioperative treatment of patients with chronic liver disease

    2020-12-16 09:00:44KamranQureshAlanBonder
    World Journal of Meta-Analysis 2020年3期
    關(guān)鍵詞:魚(yú)片剪切力微波

    Kamran Quresh,Alan Bonder

    Kamran Qureshi, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St.Louis, MO 63104, United States

    Alan Bonder, Division of Gastroenterology/Liver Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States

    Abstract

    Key words: Chronic liver disease; Thrombocytopenia; Thrombopoietin; Receptor agonist; Avatrombopag; Lusutrombopag; Romiplostim; Perioperative

    INTRODUCTION

    Thrombopoietin (TPO) is a hormone produced by the liver that regulates platelet production by binding to and activating TPO receptors that are present on the surface of megakaryocytes.This induces a series of signaling cascades, leading to increased platelet production[1].As a result, TPO levels typically decrease as liver disease progresses.This impaired TPO production, along with other factors, including platelet sequestration due to hypersplenism[2], bone marrow suppression, altered TPO metabolism, and development of anti-platelet antibodies, can contribute to thrombocytopenia[3].

    Recombinant TPOs, as a treatment option, were developed to counter the lowered TPO levels by stimulating the TPO receptor.These pharmacologic agents mimic the action of TPO by binding to and activating different receptors on the megakaryocytes.The first generation of TPO-receptor agonists (TPO-RAs) included recombinant human thrombopoietin (known as rhTPO) and pegylated-human recombinant megakaryocyte growth and development factor (known as Peg-rHuMGDF).These resulted in the development of neutralizing autoantibodies that cross-reacted with endogenous TPO and were therefore discontinued.The next-generation TPO-RAs developed did not have homology to endogenous TPO and did not, therefore, produce an antigenic effect.These included romiplostim (NPLATE?) and eltrombopag (Promacta?/Revolade?), and most recently, avatrombopag (Doptelet?) and lusutrombopag (Mulpleta?)[4-7].Of these, avatrombopag and lusutrombopag are approved by the United States Food and Drug Administration for the treatment of thrombocytopenia in patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.Hetrombopag is another TPO-RA that is currently undergoing Phase 2 trials.

    Patients with thrombocytopenia can have a negative perioperative outcome and platelet transfusions can be used to manage platelet counts during this period.Bleeding risk associated with low platelet counts has been demonstrated in several studies; however, the literature is equivocal, as some studies do not support an association.The optimal platelet count prior to performance of surgery varies, depending on the procedure and on patient variables, and while various guidelines advocate different platelet count thresholds for different invasive procedures, there are inadequate data to support these recommendations.For instance, the British Society of Hematology proposes thresholds of 50, 80 and 100 × 109/L according to the type of invasive procedure[8].

    This review will provide an overview of the currently available TPO-RAs, with a focus on their use in the perioperative setting in patients with thrombocytopenia and CLD, associated supporting clinical trials, including the efficacy and safety data, and their use with respect to platelet transfusions.

    ROMIPLOSTIM

    Efficacy and safety in clinical studies

    Romiplostim is a subcutaneously administered drug indicated in the treatment of thrombocytopenia in patients with chronic ITP who have shown an insufficient response to corticosteroids, immunoglobulins, or splenectomy.Several studies have explored the efficacy of romiplostim for the management of perioperative thrombocytopenia in patients with CLD (Table 1).However, the small sample size in these studies is a major limitation.A 3-mo, single-center, single-arm, open-label study by Moussaet al[3]evaluated the efficacy of preoperative romiplostim treatment in 35 male patients with chronic hepatitis C, liver cirrhosis, and thrombocytopenia secondary to hepatitis C virus infection over 90 d.Romiplostim administered at 2 μg/kg once a week for up to 1 mo before the scheduled surgeries resulted in an increase in platelet counts (≥ 70 × 109/L) in 33 of the 35 patients, making them eligible for the procedure.Additionally, no serious adverse events (AEs) were observed during the treatment period (up to day 30) and none of the patients experienced postoperative bleeding or a thrombotic event within 60 d of the operation[3].The authors concluded that preoperative treatment with romiplostim could be a viable and cost-effective alternative for patients who are unresponsive to standard therapy.

    A recent single-center retrospective review of 47 patients treated with romiplostim perioperatively showed that the median platelet counts improved from 47 × 109/L at the time of romiplostim initiation to 164 × 109/L at the time of surgery.Romiplostim at a dose of 3 μg/kg per week for 2 wk increased the platelet count to over 100 × 109/L in 79% of patients.Additionally, bleeding and thromboembolic events were within acceptable limits in these patients[9].The large cohort of patients, the fact that patients in this study had a wide variety of etiologies of thrombocytopenia, and that they underwent major surgical procedures, such as open cardiac surgery (unlike previous studies where procedures were minor in nature), makes this study stand out from the rest.However, the facts that this was a retrospective study without randomization, that no uniform platelet count threshold was set prior to proceeding with the medical procedure, that romiplostim doses were not standardized, and that bone marrow evaluation was not performed limits the conclusions that can be drawn[9].Nevertheless, this study provides evidence for the use of romiplostim perioperatively in patients with chronic thrombocytopenia; although, this remains an off-label use for romiplostim.

    Romiplostim treatment was also found to cause partial portal vein thrombosis (PVT), as reported for a 50-year-old woman with Child class B liver cirrhosis and hepatitis C-associated ITP; upon discontinuation of treatment complete recanalization of the portal vein was noted[10].Based on this case study, caution must be exercised in the use of romiplostim in patients with advanced liver cirrhosis.

    ELTROMBOPAG

    Eltrombopag is a small-molecule non-peptide TPO-RA that interacts with the transmembrane domain of the TPO receptor on megakaryocyte precursors and megakaryocytes, leading to increased platelet production[5].Eltrombopag is metabolizedviacleavage, oxidation, and conjugation with glucuronic acid, glutathione, or cysteine.The cytochrome P450 enzymes involved in the oxidation pathway include CTP1A2 and CYP2C8, whereas UGT1A1 and UFT1A3 are involved in the glucuronidation pathway[5].Eltrombopag increases platelet production after 7 d of repeated dosing, and platelet counts decrease to baseline 1 wk to 2 wk after discontinuing treatment[1].Eltrombopag is approved for the treatment of

    thrombocytopenia in adults and children with chronic ITP who have an insufficient response to corticosteroids, immunoglobulins, or splenectomy, in patients with chronic hepatitis C virus infection to allow initiation and maintenance of interferonbased therapy, and in patients with severe aplastic anemia who have an insufficient response to immunosuppressive therapy[5].

    Table 1 Efficacy and safety results from clinical trials studying the effect of perioperative use of thrombopoietin-receptor agonists in patients with thrombocytopenia

    Efficacy and safety in clinical studies

    The Eltrombopag Evaluated for Its Ability to Overcome Thrombocytopenia and Enable Procedures (referred to as “ELEVATE”) study was a double-blind, randomized, placebo-controlled, Phase 3 trial conducted in 288 patients with CLD and platelet counts below 50 × 109/L to study the ability of eltrombopag to increase platelet counts and to reduce the need for platelet transfusions in patients undergoing an elective invasive procedure[11].Patients received either 75 mg eltrombopag once daily or placebo.The primary efficacy endpoint was the proportion of patients who did not require a platelet transfusion before, during, and up to 7 d after the elective invasive procedure, and the secondary endpoint was the proportion of patients with bleeding before, during, and up to 7 d after the procedure.A majority of patients in the eltrombopag and placebo groups (62% and 56%, respectively) underwent elective invasive procedures that were in the lowest bleeding risk category.At the end of 2 wk, 59% of patients treated with eltrombopag and 5% of those receiving placebo had an increased platelet count, and primary endpoint was achieved in 72% and 19% of patients, respectively.With the exception of thrombotic events being higher in the eltrombopag group (4%vs1% in the placebo group), the incidence and severity of AEs were similar in both groups.Serious AEs occurred in 13% and 12% of patients in the eltrombopag and placebo groups, respectively.A total of 8 patients, comprising 6 in the eltrombopag group and 2 in the placebo group, experienced 10 thrombotic events, with 9 of those events involving the portal venous system.It must be noted that none of the 8 total patients with a thrombotic event had received both eltrombopag and a platelet/blood product transfusion, and of the 26 patients who received both eltrombopag and a transfusion, none had a thrombotic event.Additionally, 5 out of the total 8 patients who had a thrombotic event were found to have cancer.However, a separate post hoc analysis identified an association between higher platelet counts (> 200 × 109/L) and an increased risk of thrombotic events[11], and the study was terminated early due to the increased incidence of PVT in the eltrombopag arm.Key efficacy and safety data from the study are outlined in Table 1.

    In the absence of better identification of risk factors for the development of thrombotic events, dose optimization, and the risk of PVT in patients with thrombocytopenia and CLD undergoing an elective procedure, eltrombopag must be used with caution and is not recommended as an alternative to platelet transfusions in this group of patients; this is an off-label use of eltrombopag.

    結(jié)合實(shí)際實(shí)驗(yàn),最終優(yōu)化后的微波烘干鳳尾魚(yú)片的工藝參數(shù)是:烘干質(zhì)量120 g,烘干時(shí)間12 min,微波功率3 kW,最后采用該優(yōu)化參數(shù)進(jìn)行剪切力和感官評(píng)價(jià)試驗(yàn),感官評(píng)價(jià)分為94.5分,同時(shí)感官評(píng)價(jià)最佳風(fēng)味魚(yú)片的硬度值為1538.45 g,2.03%的硬度誤差和1.24%的感官評(píng)價(jià)誤差,說(shuō)明經(jīng)過(guò)響應(yīng)曲面優(yōu)化后的Y1,Y2 模型應(yīng)用于實(shí)踐中是非常可行的。

    AVATROMBOPAG

    Avatrombopag is an oral, small-molecule non-peptide TPO-RA that, like eltrombopag, binds to the TPO receptor to bring out a number of cellular reactions that give rise to megakaryocytic proliferation and differentiation and increased platelet production.Similar to eltrombopag and lusutrombopag[7], it does not compete with TPO for binding to the TPO receptor, and may thus have an additive effect with TPO on platelet production[6,12].Cytochrome P450 enzymes CYP2C9 and 3A are responsible for metabolizing avatrombopag to corresponding 4-hydroxylated products, with the former enzyme playing the predominant role[13].It is the first TPO-RA to be approved for use perioperatively to treat thrombocytopenia in adult patients with CLD scheduled to undergo a procedure[6].Avatrombopag is an orally administered drug that is taken with food for 5 d consecutively prior to an elective procedure.Avatrombopag results in a dose- and exposure-dependent increase in platelet counts in adults within 3-5 d of treatment, with a peak effect occurring after 10-13 d and counts remaining elevated over 50 × 109/L for at least 7 d post-procedure.Baseline levels are achieved after 35 d[6].

    Efficacy and safety in clinical studies

    There have been two randomized, double-blind, placebo-controlled Phase 3 trials[14]- ADAPT-1 and ADAPT-2 - with identical designs that have studied the effectiveness and safety of avatrombopag in reducing the need for platelet transfusion and rescue from bleeding in patients with CLD scheduled for a procedure.Patients were screened to exclude several criteria, including presence of arterial or venous thrombosis and a portal vein blood flow below 10 cm/s.Included patients were divided into low and high baseline platelet count cohorts and received 60 mg/d and 40 mg/d of avatrombopag, respectively.The primary endpoint of these studies was the proportion of patients who did not require a platelet transfusion or rescue procedure for bleeding after randomization and up to 7 d after a scheduled procedure.Secondary efficacy endpoints included the proportion of patients achieving the target platelet count of ≥ 50 × 109/L on the day of the procedure and the mean change in platelet count from baseline to procedure day.Patients treated with avatrombopag demonstrated increased platelet counts that were approximately 30-50 × 109/L higher on average compared with patients treated with placebo before minor invasive procedures, with a net doubling of counts on average.There were no meaningful differences in AEs of special interest among the avatrombopag-treated and placebo-treated patients, including thromboembolism, and the rates of occurrence of AEs across both the studies were comparable in the avatrombopag- and placebo-treated groups[14].A treatment-emergent AE (TEAE) of partial PVT was observed in 1 avatrombopagtreated patient in the high baseline platelet count cohort in the ADAPT-2 trial at 13 d after the last avatrombopag dose and was assessed as nonserious and possibly related to the drug.Thromboembolic events were also observed in 2 placebo-treated patients in the ADAPT-2 trial, one being an acute myocardial infarction and the other a disseminated intravascular coagulation/ pulmonary embolus.Thromboembolic TEAEs were not noted in the ADAPT-1 trial.One non-TEAE of PVT was observed in the avatrombopag group (60 mg) at 31 d after the final dose of avatrombopag and was assessed as serious but not related.Table 1 outlines the key efficacy and safety results from these trials.

    Results from a pharmacokinetic modeling study have shown that repeated dosing of avatrombopag as early as 12 d after completion of the first dosing can increase platelet counts to within safe limits[15].Saabet al[16]have recently reported that repeated dosing of avatrombopag in 4 patients with CLD and thrombocytopenia led to a 2.3-fold mean increase in platelet count after the first dosing and 2.6-fold mean increase after the second dosing.The patients underwent procedures within 9-13 d after starting avatrombopag, with repeat dosing performed at least 30 d after completing the first dose.None of the patients required platelet transfusions or rescue therapy, or had TEAEs, and repeated dosing did not reduce the efficacy of avatrombopag[16].Avatrombopag dosing has the ability to limit the magnitude and duration of increase in patient platelet counts and this predictable pharmacokinetic/pharmacodynamic profile could potentially be contributing to the limited risk of thromboembolic events associated with this treatment[14].

    LUSUTROMBOPAG

    Lusutrombopag is an orally administered, small-molecule non-peptide TPO agonist that activates the signal transduction pathways in a manner similar to endogenous TPO (while not competing for the same binding site), leading to increased platelet production[6-7].Lusutrombopag is metabolizedviathe β- and ω-oxidation pathways and glucuronidation.The cytochrome P450 enzymes are mainly responsible for its metabolism, including CYP4A11[13].The mean maximum platelet count following treatment with 3 mg/d lusutrombopag was 86.9 × 109/L and the median time to reach this was 12 d[7].

    Efficacy and safety in clinical studies

    Data from two Phase 3 double-blind studies, L-PLUS-1 and L-PLUS-2, have shown lusutrombopag to be effective in raising platelet counts in patients with CLD and thrombocytopenia prior to undergoing an elective invasive procedure.The primary endpoint of both trials was the proportion of patients who avoided pre-procedure platelet transfusions and rescue therapy for bleeding, as assessed from randomization through 7 d post-procedure[17,18].Key secondary endpoints included the number of patients who required no platelet transfusions during the study, the proportion of patients who achieved a platelet count of ≥ 50 × 109/L with an increase of ≥ 20 × 109/L from baseline at any time during the study, and the number of days during which the platelet count was maintained at ≥ 50 × 109/L[17].Safety assessments included the incidence of AEs, adverse drug reactions, bleeding-related AEs, and thrombotic events.Patients treated with lusutrombopag perioperatively demonstrated improvements in platelet counts similar to those seen with avatrombopag after 7 d of treatment.In the L-PLUS-1 trial, one serious AE of PVT, possibly related to lusutrombopag treatment, was reported in the lusutrombopag-treated group and one mild incidence of superior mesenteric vein thrombosis was reported in the placebo group that was considered not related to the study drug.As neither event was associated with an extremely high platelet count, and the incidence of thrombotic events were similar in both treatment groups, the authors concluded that no further monitoring for thromboembolic events was required in lusutrombopag-treated patients.In the L-PLUS-2 trial, four TEAEs were reported, two each in the lusutrombopag- and placebo-treated groups, respectively.All events were asymptomatic and deemed to be consistent with the findings of a meta-analysis that suggested the prevalence of PVT in patients with CLD and thrombocytopenia.Table 1 outlines the key safety and efficacy results from these trials.

    A recent retrospective report of 1760 cirrhotic patients with low platelet counts[2]found that 66% of patients with platelet counts below 50 × 109/L required platelet transfusions for radiofrequency ablation, 43% for transarterial chemoembolization, and 55% for endoscopic injection sclerotherapy/endoscopic variceal ligation.When 25 of these patients were administered lusutrombopag prior to the procedures, platelet counts increased significantly compared with baseline levels (82 × 109/Lvs41 × 109/L), and of these patients, only 4 needed platelet transfusions before the procedures.The proportion of lusutrombopag-treated patients who required platelet transfusions was significantly lower (16%) compared with patients not treated with lusutrombopag (54%)[2].Lusutrombopag was also found to be more effective in raising platelet counts in patients with baseline platelet counts above 30 × 109/L compared with patients with baseline platelet countsless than or equal to 30 × 109/L and spleen index greater than or equal to 40 cm2[2].The authors of this retrospective study reported 1 case of portal thrombosis in the lusutrombopag group, which was revealedviaa routine CT scan taken on the 12thd of treatment.The causal relationship of thrombosis with lusutrombopag treatment was unclear[2].

    Satoet al[19]were the first to report the efficacy of repeated administration of lusutrombopag (3 mg daily) in a patient with hepatocellular carcinoma who had two planned invasive procedures, radiofrequency ablation and transarterial chemoembolization.In the first instance, lusutrombopag was discontinued after 5 d, as the platelet count increased to 98 × 109/L by day 5, while in the second instance, the patient required the full 7-d treatment to achieve a platelet count above 50 × 109/L.No AEs such as portal thrombus were reported during either of the treatments.More recently, Ishikawaet al[20]reported the safety and efficacy of repeated use of lusutrombopag to increase platelet counts in 8 patients with hepatocellular carcinoma and thrombocytopenia prior to repeated scheduled radiofrequency ablation procedures.Platelet counts increased from 42500 ± 5200/μL at baseline to 103100 ± 22800/μL at day 14 after first treatment, and from 43800 ± 6000/μL at baseline to 110700 ± 17800/μL at day 14 after repeat treatment, demonstrating that the repeated use of lusutrombopag does not decrease its effect on platelet counts.None of the patients developed clinical symptoms such as thrombosis or PVT[20].

    HETROMBOPAG

    Hetrombopag is a small-molecule non-peptide TPO-RA, with a mechanism of action similar to eltrombopag but with anin vivopharmacological effect that is 8-10 times that of eltrombopag[21].Based on animal studies, it appears that hetrombopag is primarily metabolizedviaglucuronidation and hydrolyzed into aglycone following excretion with bile acid[21].A Phase 1 study demonstrated that hetrombopag is safe and welltolerated in healthy subjects and can be a potential candidate for the treatment of patients with chronic ITP[21].It is now in Phase 2 trials for the treatment of ITP.Currently, there are no clinical studies underway to examine the effectiveness and safety of hetrombopag as perioperative treatment of thrombocytopenia in patients with CLD.

    TPO-RAs FOR OTHER INDICATION UNDER INVESTIGATION

    Romiplostim and eltrombopag are currently approved for management of chronic ITP but there are studies (like the ones outlined earlier) demonstrating their efficacy in other indications.For instance, romiplostim has demonstrated efficacy in treating chemotherapy-induced thrombocytopenia and myelodysplastic syndromes[22].Eltrombopag has been shown to be effective in the treatment of hepatitis C infection (where it raises the platelet counts enough to allow continued treatment with ribavirin and pegylated-interferon), myelodysplastic syndrome, acute myeloid leukemia, and severe aplastic anemia[23].Both avatrombopag and lusutrombopag have been approved for use perioperatively to treat thrombocytopenia in patients with CLD.Recently, a supplemental New Drug Application was filed for avatrombopag as therapy for the treatment of chronic ITP; meanwhile, the trial for avatrombopag as therapy in chemotherapy-induced thrombocytopenia (NCT03471078) is still underway.A trial to study the safety and efficacy of hetrombopag (NCT03222843) for the treatment of chronic ITP is currently underway.

    RECOMMENDATIONS ON USING PLATELET TRANSFUSIONS BY SCIENTIFIC AND GOVERNING BODIES

    Patients with thrombocytopenia and CLD are at an increased risk of bleeding.Platelet transfusions can be administered in these patients prophylactically, prior to scheduled medical procedures to minimize the risk of bleeding, or therapeutically to control bleeding.The goal of any prophylactic treatment is limiting hemorrhagic events in the peri- and post-operative surgical setting.However, there is uncertainty in prophylactic treatment of thrombocytopenia, as there are no effective tools that can predict bleeding risk in patients, and data on the correlation between thrombocytopenia and the risk of bleeding are equivocal[24,25].While platelet transfusion is a primary option in these patients, the decision to undergo transfusion can be a complicated one.

    Lack of consensus among guidelines

    There is a lack of consensus among guidelines related to platelet transfusion in patients, primarily due to lack of sufficient and supportive data to substantiate the recommended platelet transfusion triggers[26].Further, there are no guidelines that provide recommendations for platelet transfusion specifically for patients with CLD prior to an elective procedure.The variations in the recommended platelet threshold values before invasive procedures often depend on the type of patient and the perceived risk of the procedure.The American Society for Gastrointestinal Endoscopy (ASGE) guidelines[27], which are not specific to gastrointestinal bleeding, state that the minimum threshold platelet count for undergoing upper gastrointestinal endoscopy has not been established, but they also point out that there are publications supporting 20 × 109/L and 50 × 109/L as the threshold for platelet counts prior to diagnostic procedures and biopsies, respectively.The American Association for the Study of Liver Diseases guidelines for transcutaneous or transvenous liver biopsy state that platelet transfusions should be considered when platelet counts are less than 50-60 × 109/L[28], and the ASGE guidelines recommend platelet transfusions only in case of severe thrombocytopenia[29].The current American Society of Hematology guidelines recommend the use of corticosteroids as first-line treatment in newly diagnosed adults with a platelet count less than 30 × 109/L who are symptomatic or have minor mucocutaneous bleeding.In adults with ITP ≥ 3 mo who are corticosteroid-dependent or unresponsive to corticosteroids, the guidelines suggest treatment with TPO-RA eltrombopag or romiplostim.The guidelines recommend second-line treatment to be individualized, based on duration of disease and patient preferences; however, they provide no recommendations regarding the use of therapies prior to undergoing an invasive procedure or treatment[30].

    The updated (2019) International Consensus Report on Management of ITP recommends target platelet counts above 50 × 109/L for minor surgery, above 80 × 109/L for major surgery, and above 100 × 109/L for major neurosurgery[31].The National Institute for Health and Care Excellence guidelines recommend prophylactic platelet transfusions in patients who are having invasive procedures or surgery, in order to raise the platelet counts above 50 × 109/L.They advocate a higher threshold (50-60 × 109/L) for patients with a high risk of bleeding who are having invasive procedures or surgery after taking into account the type of procedure, the cause of thrombocytopenia, any coexisting causes of abnormal hemostasis, and whether the patient’s baseline platelet count is falling.These guidelines also recommend prophylactic platelet transfusions to raise the platelet counts above 100 × 109/L in patients having surgery at critical sites, such as the central nervous system, whereas they do not recommend transfusions for patients having procedures with a low risk of bleeding, such as central venous cannulation or bone marrow aspiration[32].The American Association of Blood Banks guidelines recommend prophylactic platelet transfusion for minor invasive procedures, such as central venous catheter placement at platelet counts ≤ 20 × 109/L and for major non-neuraxial surgery at platelet counts ≤ 50 × 109/L, but do not make recommendations for bleeding patients with thrombocytopenia[29].

    Downsides of platelet transfusions

    The choice of initiating platelet transfusions can also be complicated due to the associated risks.Platelet transfusions have been associated with a number of blood transfusion reactions, the possibility of fatal complications (i.e.sepsis), proinflammatory responses, febrile non-hemolytic reactions, and acute lung injury[33].There is also the risk for development of refractoriness that can prevent further platelet transfusions which can, in turn, lead to decreased survival, prolonged hospital stays, and increased healthcare costs[13,34].A major limitation of platelet transfusions is the short lifespan of platelets, which require use to occur within 4 d of obtainment to prevent bacterial growth[33].There is also a shortage of platelets currently, due to the decline in blood collection and utilization[35].

    While platelet transfusions can effectively increase platelet counts in the perioperative setting, factors such as alloimmunization or personal beliefs (e.g.Jehovah’s Witnesses), suggest a need for alternatives[9].

    GUIDANCE ON USE OF TPO-RAs

    The treatment of patients with thrombocytopenia who require a medical procedure is variable and uncertain, as there are limited data to inform decisions.The aim of the treating physician is to minimize bleeding and improve clinical outcomes.Even though guidelines have no consensus on the threshold for platelet transfusion, most do support raising the platelet levels (to varying degrees) prior to procedures.This, combined with the risk associated with platelet transfusions, may make TPO-RAs an alternative to platelet transfusions in patients with CLD.

    An ideal treatment for thrombocytopenia in patients with CLD undergoing an invasive procedure would have the following characteristics: (1) Effectiveness; (2) Oral bioavailability; (3) Minimal adverse effects; and (4) Cost-effectiveness.Neither platelet transfusions nor TPO-RAs satisfy all these requirements.Table 2 lists the key safety and tolerability information for each TPO-RA approved for use.Unlike platelet transfusions, TPO-RAs are not capable of increasing platelet counts rapidly, as the platelet counts increase approximately 5-7 d after and peak approximately 10-14 d after administration of a TPO-RA[36].Therefore, one potential disadvantage of TPORAs is the lag time between dosage and increased platelet numbers, as it prevents the use of TPO-RAs in emergent situations.The advantages of TPO-RAs include oral bioavailability (except in case of romiplostim, which is administered subcutaneously), their ability to increase platelet counts endogenously, and sustaining the increase over a longer duration compared to that produced by platelet transfusions and thereby reducing the need for rescue therapy while causing fewer procedure-related complications than platelet transfusions.Avatrombopag and lusutrombopag are currently the only TPO-RAs approved for the perioperative treatment of thrombocytopenia in patients with CLD, and compared with romiplostim and eltrombopag, they are associated with a decreased risk of thromboembolic and hepatic events.Nevertheless, platelet counts must be measured during treatment, as counts higher than 200 × 109/L have been shown to be associated with serious AEs, such as PVT.Both avatrombopag and lusutrombopag may be used in cirrhotic patients with low platelet counts scheduled to undergo an elective procedure with bleeding risks and in patients who cannot undergo platelet transfusions (Figure 1).Depending on the pre-procedure platelet counts, patients should be treated with either 40 mg or 60 mg of avatrombopag; the dose of lusutrombopag is always 3 mg.The window for undergoing procedures following dosing with avatrombopag and lusutrombopag is between 9-13 d and 8-14 d, respectively.It must be noted that while clinical trials with avatrombopag and lusutrombopag excluded patients with PVT, a PVT-prescreen is

    not a requirement as per labeling guidelines for both these TPO-RAs.Patients with liver cirrhosis and high Child-Turcotte-Pugh scores are more likely to have severe thrombocytopenia and also require invasive diagnostic procedures.Extreme caution must be taken when using TPO-RAs in such patients, as they are at high risk of developing PVT; currently, no data on the effects of the TPO-RAs avatrombopag and lusutrombopag in this class of patients are available, as they were excluded from the clinical trials[14,16-18].

    Table 2 Key safety and tolerability information for thrombopoietin-receptor agonists approved for use[4-7]

    Figure 1 Patient criteria and general schema for administration of oral thrombopoietin-receptor agonists in patients with chronic liver disease and thrombocytopenia scheduled to undergo a procedure.

    There are also pricing differences between avatrombopag and lusutrombopag; in the United States, the wholesale acquisition cost (WAC) of avatrombopag for a 5-d course is $2970 for the 40-mg dose and $4455 for the 60-mg dose.The WAC for a 7-d course of lusutrombopag is $8500[37].

    CONCLUSION

    Recommendations for procedure-specific minimum platelet counts prior to a scheduled procedure often have inadequate supporting evidence, and the benefit of prophylactic platelet transfusion remains unclear.Physicians typically assess the need for platelet transfusions on a patient-to-patient basis, relying on their own experience and patient comorbidities to inform their decisions.TPO-RAs are a safe and effective alternative treatment option for patients with thrombocytopenia who are undergoing a medical procedure.They are associated with increased platelet counts, decreased bleeding events, and a reduced need for rescue treatments.Recent studies also support the safe and efficacious repeated use of TPO-RAs in patients with CLD.The exact fit of TPO-RAs, as compared with platelet transfusions, in patients with thrombocytopenia prior to undergoing a medical procedure is still unclear.Comparative clinical trial data in patients with thrombocytopenia are required to assess the efficacy, safety, costeffectiveness, and impact on patient quality of life of TPO-RA use compared with the traditional use of platelet transfusions prior to scheduling a medical procedure.In the meantime, treatment decisions must be individualized by establishing the advantages and disadvantages of both these treatment options on a case-by-case basis.

    猜你喜歡
    魚(yú)片剪切力微波
    微波水云間
    保健與生活(2023年6期)2023-03-17 08:39:54
    一種汽車(chē)發(fā)動(dòng)機(jī)用橡膠減震器
    基于Fluent的不同彎道剪切力分布特性數(shù)值研究
    為什么
    微波冷笑話
    金色年華(2017年12期)2017-07-18 11:11:20
    煲魚(yú)湯高招
    水流剪切力對(duì)供水管道管壁生物膜生長(zhǎng)的影響
    糟溜魚(yú)片
    餐飲世界(2015年1期)2015-05-04 11:54:00
    冷藏期間草魚(yú)魚(yú)片脂肪氧化變化規(guī)律研究
    底層隔板法流體壁面剪切力的測(cè)量研究
    国产精品不卡视频一区二区| av天堂在线播放| 婷婷六月久久综合丁香| 深爱激情五月婷婷| bbb黄色大片| 又爽又黄a免费视频| 亚洲国产精品合色在线| eeuss影院久久| 亚洲最大成人av| 99精品久久久久人妻精品| 国产aⅴ精品一区二区三区波| 黄色配什么色好看| 村上凉子中文字幕在线| 一个人免费在线观看电影| 非洲黑人性xxxx精品又粗又长| 午夜精品一区二区三区免费看| 麻豆成人av在线观看| 3wmmmm亚洲av在线观看| 一夜夜www| 美女高潮的动态| 亚洲中文日韩欧美视频| av.在线天堂| 午夜福利欧美成人| 久久6这里有精品| 久久久国产成人精品二区| 午夜免费男女啪啪视频观看 | 精品乱码久久久久久99久播| 亚洲四区av| 国产精品永久免费网站| 国产熟女欧美一区二区| 美女高潮喷水抽搐中文字幕| 久9热在线精品视频| 国产高清三级在线| 日本黄色视频三级网站网址| 亚洲18禁久久av| 久久亚洲真实| 老女人水多毛片| 黄色日韩在线| 亚州av有码| www.www免费av| 别揉我奶头 嗯啊视频| 欧美日韩瑟瑟在线播放| 一区福利在线观看| 亚洲va在线va天堂va国产| 久久精品国产亚洲av天美| 欧美人与善性xxx| 国产男靠女视频免费网站| 欧美日韩中文字幕国产精品一区二区三区| 美女高潮的动态| av在线亚洲专区| 亚洲真实伦在线观看| 综合色av麻豆| 久久草成人影院| 国产免费男女视频| 久久婷婷人人爽人人干人人爱| 女人十人毛片免费观看3o分钟| 成年女人毛片免费观看观看9| 色5月婷婷丁香| 人人妻人人澡欧美一区二区| av视频在线观看入口| 中出人妻视频一区二区| h日本视频在线播放| 一区福利在线观看| 午夜福利视频1000在线观看| 国产伦精品一区二区三区四那| 国产高潮美女av| АⅤ资源中文在线天堂| 免费在线观看成人毛片| 欧美精品啪啪一区二区三区| www.色视频.com| 久久午夜福利片| 中文字幕人妻熟人妻熟丝袜美| 熟女电影av网| 哪里可以看免费的av片| 1024手机看黄色片| 在线观看舔阴道视频| 亚洲精品一区av在线观看| 国产精品精品国产色婷婷| 桃色一区二区三区在线观看| 网址你懂的国产日韩在线| 一区福利在线观看| a在线观看视频网站| 国产色爽女视频免费观看| 国产午夜福利久久久久久| 国产欧美日韩精品亚洲av| 久9热在线精品视频| 日日摸夜夜添夜夜添小说| 男女啪啪激烈高潮av片| 国产高清有码在线观看视频| 在线播放国产精品三级| 色哟哟哟哟哟哟| 亚洲熟妇熟女久久| 成人鲁丝片一二三区免费| 国产探花极品一区二区| 日日撸夜夜添| 欧美xxxx性猛交bbbb| 国产亚洲精品综合一区在线观看| 午夜福利欧美成人| 国产精品嫩草影院av在线观看 | 男女做爰动态图高潮gif福利片| 欧美成人a在线观看| 别揉我奶头 嗯啊视频| 亚洲成人免费电影在线观看| 亚洲无线在线观看| 欧美高清性xxxxhd video| 免费av不卡在线播放| 色吧在线观看| 亚洲成a人片在线一区二区| 欧美绝顶高潮抽搐喷水| 免费电影在线观看免费观看| 在线免费观看不下载黄p国产 | 久久午夜福利片| 国产色爽女视频免费观看| 两个人的视频大全免费| 黄色视频,在线免费观看| 欧美丝袜亚洲另类 | 桃红色精品国产亚洲av| 亚洲午夜理论影院| 日韩欧美一区二区三区在线观看| 毛片女人毛片| 色5月婷婷丁香| 3wmmmm亚洲av在线观看| 亚洲精品久久国产高清桃花| 日韩大尺度精品在线看网址| 一级a爱片免费观看的视频| 欧美黑人巨大hd| 国产在线精品亚洲第一网站| 午夜免费成人在线视频| 一边摸一边抽搐一进一小说| 美女被艹到高潮喷水动态| 人人妻人人澡欧美一区二区| 久久久久国内视频| 波多野结衣巨乳人妻| 欧美日本亚洲视频在线播放| 一边摸一边抽搐一进一小说| 日韩在线高清观看一区二区三区 | 国产国拍精品亚洲av在线观看| 毛片女人毛片| 欧美激情国产日韩精品一区| 日韩欧美三级三区| 成人鲁丝片一二三区免费| 老熟妇乱子伦视频在线观看| 国产一区二区在线av高清观看| 日本撒尿小便嘘嘘汇集6| 日本熟妇午夜| 国产精品一区二区三区四区久久| 99热这里只有是精品在线观看| 午夜日韩欧美国产| 国产精品久久久久久精品电影| 亚洲av免费高清在线观看| 色综合婷婷激情| 国产真实伦视频高清在线观看 | 亚洲成人久久性| 欧美性感艳星| 国产aⅴ精品一区二区三区波| 22中文网久久字幕| 欧美成人性av电影在线观看| 久久人妻av系列| 22中文网久久字幕| 欧美xxxx黑人xx丫x性爽| 成人综合一区亚洲| 免费看a级黄色片| 性插视频无遮挡在线免费观看| 国产高清三级在线| 婷婷色综合大香蕉| 国产人妻一区二区三区在| 国产伦在线观看视频一区| 久久这里只有精品中国| 99热6这里只有精品| 一个人看视频在线观看www免费| 色综合亚洲欧美另类图片| 久9热在线精品视频| 国产伦在线观看视频一区| 99久久精品热视频| 在线看三级毛片| 国产精品1区2区在线观看.| 长腿黑丝高跟| 99热这里只有是精品在线观看| 黄色日韩在线| 欧美性感艳星| 国产探花在线观看一区二区| 精品国产三级普通话版| 美女 人体艺术 gogo| 亚洲国产精品合色在线| 国产av不卡久久| 又爽又黄无遮挡网站| 国产老妇女一区| 成人特级av手机在线观看| 极品教师在线视频| 亚洲精品亚洲一区二区| 高清毛片免费观看视频网站| 真人做人爱边吃奶动态| 我的女老师完整版在线观看| 真人一进一出gif抽搐免费| 亚洲三级黄色毛片| 观看免费一级毛片| 毛片女人毛片| 亚洲av不卡在线观看| 精品一区二区三区av网在线观看| 欧美日本视频| 国产乱人视频| 97碰自拍视频| 欧美激情久久久久久爽电影| 国产午夜精品久久久久久一区二区三区 | 成熟少妇高潮喷水视频| h日本视频在线播放| 亚州av有码| 在现免费观看毛片| 真人做人爱边吃奶动态| 美女免费视频网站| 国产精品久久久久久av不卡| 国产aⅴ精品一区二区三区波| 国产极品精品免费视频能看的| 欧美一区二区国产精品久久精品| 午夜激情福利司机影院| 91在线观看av| av天堂在线播放| 欧美激情在线99| 黄色丝袜av网址大全| 在线观看66精品国产| 我的女老师完整版在线观看| 男人的好看免费观看在线视频| 久久人妻av系列| 12—13女人毛片做爰片一| 国产精品一区二区三区四区久久| 国产淫片久久久久久久久| 色综合婷婷激情| 22中文网久久字幕| 日韩强制内射视频| 熟女人妻精品中文字幕| 色5月婷婷丁香| 色噜噜av男人的天堂激情| videossex国产| 黄色丝袜av网址大全| 九九在线视频观看精品| 丰满的人妻完整版| 国产亚洲精品久久久com| 亚洲不卡免费看| 在线a可以看的网站| 亚洲成人中文字幕在线播放| 久久6这里有精品| 日本三级黄在线观看| 伦理电影大哥的女人| avwww免费| 色综合站精品国产| 熟女人妻精品中文字幕| 精品久久久噜噜| 免费av不卡在线播放| 国产主播在线观看一区二区| 69人妻影院| 亚洲不卡免费看| 午夜免费男女啪啪视频观看 | 午夜福利高清视频| 久久精品综合一区二区三区| 可以在线观看的亚洲视频| 日日摸夜夜添夜夜添小说| 国内少妇人妻偷人精品xxx网站| 五月玫瑰六月丁香| 亚洲av免费高清在线观看| 国产亚洲精品av在线| 日韩欧美一区二区三区在线观看| 18禁裸乳无遮挡免费网站照片| 色综合婷婷激情| 国产精品,欧美在线| 91麻豆av在线| 久久欧美精品欧美久久欧美| 能在线免费观看的黄片| 我的老师免费观看完整版| 亚洲黑人精品在线| 国产精品99久久久久久久久| 黄色视频,在线免费观看| 亚洲欧美日韩高清在线视频| 99久久中文字幕三级久久日本| 99久国产av精品| 日韩一本色道免费dvd| a在线观看视频网站| 黄色配什么色好看| 精品久久久久久久久久久久久| 国产午夜福利久久久久久| 淫秽高清视频在线观看| 色尼玛亚洲综合影院| 波多野结衣高清无吗| 最近视频中文字幕2019在线8| 老司机福利观看| 免费看光身美女| 精品午夜福利在线看| 成年免费大片在线观看| 久久精品国产亚洲av涩爱 | 成人精品一区二区免费| 人人妻,人人澡人人爽秒播| 亚洲av熟女| 久久久久久久亚洲中文字幕| 嫩草影视91久久| 久久久久久久精品吃奶| 九色国产91popny在线| 成人特级黄色片久久久久久久| 十八禁网站免费在线| 99riav亚洲国产免费| 国产在线精品亚洲第一网站| 日韩欧美 国产精品| 淫秽高清视频在线观看| 欧美中文日本在线观看视频| 人妻制服诱惑在线中文字幕| 成人国产麻豆网| 精品一区二区三区视频在线| av在线亚洲专区| 久久这里只有精品中国| 久久天躁狠狠躁夜夜2o2o| 国内精品久久久久精免费| 此物有八面人人有两片| 亚洲av第一区精品v没综合| 亚洲第一电影网av| 老熟妇仑乱视频hdxx| 国产精品自产拍在线观看55亚洲| 18+在线观看网站| 亚洲av美国av| 又黄又爽又刺激的免费视频.| avwww免费| 久久草成人影院| 亚洲真实伦在线观看| 亚洲成人久久爱视频| 欧美三级亚洲精品| 男人的好看免费观看在线视频| 亚洲av二区三区四区| 男女之事视频高清在线观看| 熟妇人妻久久中文字幕3abv| 午夜亚洲福利在线播放| a级一级毛片免费在线观看| 国产不卡一卡二| 美女 人体艺术 gogo| 国产高潮美女av| 亚洲四区av| 夜夜看夜夜爽夜夜摸| 一边摸一边抽搐一进一小说| 亚洲成人免费电影在线观看| www.www免费av| 亚洲经典国产精华液单| 亚洲精品影视一区二区三区av| 看免费成人av毛片| 美女xxoo啪啪120秒动态图| 日韩欧美在线乱码| 国产精品自产拍在线观看55亚洲| 亚洲无线观看免费| 欧美一区二区亚洲| 国产伦在线观看视频一区| 最近视频中文字幕2019在线8| 少妇的逼水好多| 国产亚洲91精品色在线| 成人欧美大片| 国产国拍精品亚洲av在线观看| 如何舔出高潮| 亚洲国产高清在线一区二区三| 九九热线精品视视频播放| 成人亚洲精品av一区二区| 成年女人看的毛片在线观看| 国产精品爽爽va在线观看网站| 高清毛片免费观看视频网站| 波多野结衣巨乳人妻| 91av网一区二区| 男插女下体视频免费在线播放| 国产午夜精品论理片| 免费电影在线观看免费观看| xxxwww97欧美| 又黄又爽又免费观看的视频| 久久婷婷人人爽人人干人人爱| 少妇人妻精品综合一区二区 | 欧美一区二区国产精品久久精品| 国产视频内射| 免费av不卡在线播放| 久久久精品欧美日韩精品| 午夜免费男女啪啪视频观看 | 久久99热6这里只有精品| 男人舔奶头视频| x7x7x7水蜜桃| 国产精品无大码| 久久草成人影院| 亚洲精品日韩av片在线观看| 亚洲av电影不卡..在线观看| 婷婷六月久久综合丁香| 亚洲第一电影网av| 国产成年人精品一区二区| 日本一本二区三区精品| 床上黄色一级片| 99久久精品一区二区三区| 国产黄a三级三级三级人| 啦啦啦韩国在线观看视频| 变态另类丝袜制服| 99热这里只有是精品50| 最新中文字幕久久久久| 桃色一区二区三区在线观看| 1000部很黄的大片| 嫩草影院新地址| 淫妇啪啪啪对白视频| 久久国产乱子免费精品| bbb黄色大片| 波野结衣二区三区在线| 极品教师在线免费播放| 精品久久久噜噜| 国产免费av片在线观看野外av| 亚洲av免费高清在线观看| 白带黄色成豆腐渣| 淫秽高清视频在线观看| 九色国产91popny在线| 欧美bdsm另类| 狂野欧美白嫩少妇大欣赏| 国产乱人伦免费视频| or卡值多少钱| 啦啦啦韩国在线观看视频| 国产精品久久久久久亚洲av鲁大| 午夜免费激情av| 国产亚洲精品av在线| 天堂√8在线中文| 国产av一区在线观看免费| 日韩欧美精品v在线| 日本欧美国产在线视频| 尾随美女入室| 他把我摸到了高潮在线观看| 一级av片app| 国产高潮美女av| 色精品久久人妻99蜜桃| 欧美激情国产日韩精品一区| 97超视频在线观看视频| 女的被弄到高潮叫床怎么办 | 国产精华一区二区三区| 中文字幕av在线有码专区| 国产私拍福利视频在线观看| 免费看日本二区| 免费在线观看影片大全网站| 亚洲黑人精品在线| 赤兔流量卡办理| 少妇人妻一区二区三区视频| 国产中年淑女户外野战色| 欧美区成人在线视频| 一夜夜www| 亚洲中文日韩欧美视频| 日本精品一区二区三区蜜桃| 99热精品在线国产| 国产精品女同一区二区软件 | 春色校园在线视频观看| 99精品久久久久人妻精品| 又粗又爽又猛毛片免费看| 成人鲁丝片一二三区免费| 久久精品久久久久久噜噜老黄 | 淫秽高清视频在线观看| 少妇熟女aⅴ在线视频| 午夜福利在线观看吧| 亚洲第一区二区三区不卡| 人妻少妇偷人精品九色| 亚洲欧美日韩无卡精品| 日本三级黄在线观看| 深夜精品福利| 欧美日本视频| 亚洲精品影视一区二区三区av| 日本-黄色视频高清免费观看| 18禁黄网站禁片午夜丰满| 精品久久久久久,| 欧洲精品卡2卡3卡4卡5卡区| 久久人人爽人人爽人人片va| 中国美白少妇内射xxxbb| 小蜜桃在线观看免费完整版高清| 在线观看一区二区三区| 国产成人a区在线观看| 欧美性猛交黑人性爽| 日韩国内少妇激情av| av视频在线观看入口| 免费av不卡在线播放| 国产欧美日韩一区二区精品| 国产三级在线视频| 日本在线视频免费播放| 麻豆国产97在线/欧美| 成人永久免费在线观看视频| 午夜福利在线观看吧| 国产高潮美女av| 女人被狂操c到高潮| 国产免费av片在线观看野外av| 国产色婷婷99| 观看美女的网站| 国产高清不卡午夜福利| 日韩 亚洲 欧美在线| 久久国产乱子免费精品| 久久国产精品人妻蜜桃| 听说在线观看完整版免费高清| 看免费成人av毛片| 久久午夜亚洲精品久久| 自拍偷自拍亚洲精品老妇| 亚洲图色成人| 国产一区二区亚洲精品在线观看| 亚洲国产精品合色在线| 精品欧美国产一区二区三| 日韩欧美国产一区二区入口| 日韩欧美在线二视频| 哪里可以看免费的av片| 亚洲欧美日韩东京热| 岛国在线免费视频观看| 亚洲国产精品合色在线| 亚洲aⅴ乱码一区二区在线播放| 日本熟妇午夜| 天美传媒精品一区二区| 免费一级毛片在线播放高清视频| 97超视频在线观看视频| 中文在线观看免费www的网站| 国产主播在线观看一区二区| 99热这里只有精品一区| 搡老岳熟女国产| 免费看av在线观看网站| 亚洲乱码一区二区免费版| 毛片女人毛片| 动漫黄色视频在线观看| 亚洲精品久久国产高清桃花| 亚洲,欧美,日韩| 乱人视频在线观看| 亚洲成av人片在线播放无| 哪里可以看免费的av片| 人妻丰满熟妇av一区二区三区| 十八禁网站免费在线| 别揉我奶头~嗯~啊~动态视频| 精品国内亚洲2022精品成人| 久久精品影院6| 国产探花在线观看一区二区| 久久人人爽人人爽人人片va| 久久久久久久亚洲中文字幕| 国产精品,欧美在线| 国产综合懂色| 日日撸夜夜添| 老女人水多毛片| 亚州av有码| 久久久久久久亚洲中文字幕| 成人三级黄色视频| 性欧美人与动物交配| 午夜影院日韩av| 久久精品国产99精品国产亚洲性色| 国产精品无大码| 中出人妻视频一区二区| 久久精品国产自在天天线| 欧美日韩亚洲国产一区二区在线观看| 黄片wwwwww| 亚洲av不卡在线观看| 日本 av在线| 欧洲精品卡2卡3卡4卡5卡区| 黄色女人牲交| 国产综合懂色| 九色成人免费人妻av| 在线国产一区二区在线| 深爱激情五月婷婷| 国产精品乱码一区二三区的特点| 丝袜美腿在线中文| 免费av不卡在线播放| 男插女下体视频免费在线播放| 亚洲一区二区三区色噜噜| 91久久精品国产一区二区成人| 久久99热6这里只有精品| 久久精品人妻少妇| 热99re8久久精品国产| 欧美又色又爽又黄视频| 国产麻豆成人av免费视频| 久久精品人妻少妇| 日本黄色片子视频| av国产免费在线观看| 亚洲图色成人| 亚洲自偷自拍三级| 麻豆一二三区av精品| 欧美性感艳星| 老熟妇乱子伦视频在线观看| 久久久久国内视频| 麻豆久久精品国产亚洲av| 99热6这里只有精品| 久久国产乱子免费精品| 亚洲美女搞黄在线观看 | 国产不卡一卡二| 级片在线观看| 天堂√8在线中文| 在线国产一区二区在线| 亚洲av一区综合| 老熟妇乱子伦视频在线观看| 美女cb高潮喷水在线观看| 一进一出抽搐gif免费好疼| 久久久久性生活片| 国产一区二区在线观看日韩| 国产久久久一区二区三区| 亚洲国产欧美人成| 变态另类成人亚洲欧美熟女| 国产69精品久久久久777片| 国产欧美日韩精品亚洲av| 免费无遮挡裸体视频| aaaaa片日本免费| 在线免费观看的www视频| 看免费成人av毛片| 美女 人体艺术 gogo| 在线免费观看的www视频| 人妻制服诱惑在线中文字幕| 无人区码免费观看不卡| 国产精品国产三级国产av玫瑰| 亚洲最大成人中文| 三级毛片av免费| 97超视频在线观看视频| 成人国产综合亚洲| 精品无人区乱码1区二区| 美女高潮喷水抽搐中文字幕| 伦理电影大哥的女人| 在线看三级毛片| 欧美精品国产亚洲| 免费av不卡在线播放| 女人被狂操c到高潮| 亚洲国产欧美人成| 夜夜看夜夜爽夜夜摸| 校园春色视频在线观看| 欧美性猛交╳xxx乱大交人| 两个人的视频大全免费| 在线播放国产精品三级| 午夜亚洲福利在线播放| 男女啪啪激烈高潮av片| 十八禁国产超污无遮挡网站| 国产高清有码在线观看视频| 欧美又色又爽又黄视频| 啦啦啦观看免费观看视频高清|